<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="567">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05153772</url>
  </required_header>
  <id_info>
    <org_study_id>135150</org_study_id>
    <nct_id>NCT05153772</nct_id>
  </id_info>
  <brief_title>Targeted Alpha-emitter Therapy of PRRT Naive Neuroendocrine Tumor Patients</brief_title>
  <acronym>ALPHAMEDIX02</acronym>
  <official_title>A Phase 2 Open Label Study to Evaluate the Safety and Effectiveness of 212Pb-DOTAMTATE in PRRT Naive Subjects With Somatostatin Receptor Expressing Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiomedix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orano Med LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radiomedix, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive&#xD;
      somatostatin positive neuroendocrine tumors with no prior history of peptide receptor&#xD;
      radionuclide therapy (PRRT naive)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this open-label, multicenter, single-arm Phase 2 study, adult subjects with histologically&#xD;
      confirmed NETs and positive somatostatin analog imaging, with no prior PRRT (PRRT naive) will&#xD;
      be enrolled to receive 212Pb-DOTAMTATE 67.6 μCi/kg dose per cycle&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of the objective response rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.</measure>
    <time_frame>24 months after last dose administration</time_frame>
    <description>The morphological imaging (CT/MRI) will be done before therapy and selected time points before therapy cycle to determine changes in the size of target lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with treatment-related adverse events as assessed by CTCAE v.4.0</measure>
    <time_frame>24 months after last dose administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of the Median Progression free survival (mPFS)</measure>
    <time_frame>24 months after last dose administration</time_frame>
    <description>PFS will be defined as the number of days from the first dose of 212Pb-DOTAMTATE to documented tumor progression per RECIST 1.1 criteria or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Overall Survival (OS)</measure>
    <time_frame>24 months after last dose administration</time_frame>
    <description>OS will be defined as the number of days from the first dose of 212Pb-DOTAMTATE to the date of death due to any cause or the date of last contact (censored observations) at the data cut-off date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Time to Tumor Progression (TTP)</measure>
    <time_frame>24 months after last dose administration</time_frame>
    <description>This measurement will determine the time from start of treatment with 212Pb- DOTAMTATE until disease progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Pb212-DOTAMTATE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>investigational radiotherapeutic drug targeting somatostatin receptor-positive neuroendocrine tumors</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AlphaMedix</intervention_name>
    <description>212Pb-DOTAMTATE is a radiolabeled derivative of octreotide targeting somatostatin positive neuroendocrine tumors</description>
    <arm_group_label>Pb212-DOTAMTATE</arm_group_label>
    <other_name>Pb212-octreotide analog</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female ≥18 years old with unresectable or metastatic histologically confirmed&#xD;
             NET&#xD;
&#xD;
          -  Documented progression of disease following previous therapy within 12 months prior to&#xD;
             enrollment and the presence of at least 1 site of measurable disease per RECIST 1.1;&#xD;
&#xD;
          -  Subjects must have received and progressed following somatostatin analog&#xD;
             administration.&#xD;
&#xD;
          -  Confirmed presence of somatostatin receptors on all lesions including the non-target&#xD;
             and measurable lesions documented by CT/MRI scans, based on positive 68Ga-DOTATATE&#xD;
             (NETSPOT®), 64Cu-DOTATATE (Detectnet™), or other FDA approved SSTR PET/CT imaging&#xD;
             within 6 weeks prior to enrollment. Follow up imaging should be performed with the&#xD;
             same agent or modality used at baseline;&#xD;
&#xD;
               1. Target lesions must be positive (greater than grade 2 uptake Krenning Score) or&#xD;
                  must have an SUV of more than the normal liver background.&#xD;
&#xD;
               2. Lytic bone lesions, with an identifiable soft tissue component, evaluated by CT&#xD;
                  or MRI, can also be considered measurable lesions if the soft tissue component&#xD;
                  otherwise meets the definition of measurability according to RECIST 1.1. In any&#xD;
                  case, osteoblastic bone lesions are not measurable.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) status 0-2;&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks in the opinion of the investigator at the time of&#xD;
             screening;&#xD;
&#xD;
          -  Sufficient bone marrow capacity and organ function in the recent blood tests within 3&#xD;
             weeks prior to Day 1, as defined by:&#xD;
&#xD;
               1. White blood cell (WBC) ≥2,500/ mm3;&#xD;
&#xD;
               2. Absolute neutrophil count (ANC) ≥1000/mm3;&#xD;
&#xD;
               3. Platelets ≥100,000/mm3;&#xD;
&#xD;
               4. Hemoglobin (HgB) ≥9.0 g/dL;&#xD;
&#xD;
               5. Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤3 X upper&#xD;
                  limit of normal (ULN);&#xD;
&#xD;
               6. Total Bilirubin: ≤2 X ULN;&#xD;
&#xD;
               7. Serum creatinine ≤1.7 mg/dL;&#xD;
&#xD;
               8. Serum albumin ≥3.0 g/L; if lower than 3.0 g/L requires normal range prothrombin&#xD;
                  time (PT) and international normalized ratio (INR), and&#xD;
&#xD;
          -  Be willing to practice the following medically acceptable methods of birth control&#xD;
             (both women of childbearing potential (WOCBP) and men who have partners of&#xD;
             childbearing potential) from the Screening Visit through 3 months after the final&#xD;
             administration 212Pb-DOTAMTATE&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior whole-body radiotherapy or PRRT using 177Lu/90Y/111In-DOTATATE/ DOTATOC or TAT.&#xD;
&#xD;
          -  Prior regional hepatic radionuclide therapy within 4 months prior to enrollment or&#xD;
             prior nonradioactive regional hepatic therapy within 6 months prior to enrollment.&#xD;
&#xD;
          -  Known hypersensitivity to somatostatin analogues, AA infusion, or 212Pb-DOTAMTATE;&#xD;
&#xD;
          -  Therapeutic use of any somatostatin analogue, including Sandostatin® LAR (within 28&#xD;
             days) and Sandostatin® (within 1 day) prior to administration of study drug;&#xD;
&#xD;
          -  History of myelodysplastic syndrome (MDS);&#xD;
&#xD;
          -  Female subjects who are pregnant or lactating;&#xD;
&#xD;
          -  Indication for surgical lesion removal with curative potential;&#xD;
&#xD;
          -  Known brain metastases, unless these metastases have been treated and/or stable for 6&#xD;
             months prior to enrollment;&#xD;
&#xD;
          -  Experimental cancer treatments or other investigational therapies within 6 weeks or&#xD;
             five half-lives of the investigational medication prior to Day 1;&#xD;
&#xD;
          -  Uncontrolled congestive heart failure (NYHA II, III, IV);&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus as defined by a hemoglobin A1C &gt;10.0;&#xD;
&#xD;
          -  Evidence of renal obstruction based on Tc-99m DTPA or TER for MAG3 renal scintigraphy&#xD;
             or renal ultrasound.&#xD;
&#xD;
          -  Known or active human immunodeficiency virus (HIV) or hepatitis B or C virus unless&#xD;
             cured;&#xD;
&#xD;
          -  Known or suspected active drug or alcohol abuse;&#xD;
&#xD;
          -  Participation in other interventional clinical studies within 30 days prior to Day 1;&#xD;
&#xD;
          -  Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in&#xD;
             situ of the uterine cervix, unless definitively treated and proven no evidence of&#xD;
             recurrence for 5 years;&#xD;
&#xD;
          -  Any somatic or psychiatric disease/condition or abnormal laboratory test that in the&#xD;
             opinion of the investigator, may interfere with the objectives and assessments of the&#xD;
             study; or&#xD;
&#xD;
          -  Unable to comply with the requirements of the study protocol or be unsuitable for the&#xD;
             study for any reason, in the opinion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ebrahim S Delpassand, MD</last_name>
    <phone>7134999733</phone>
    <email>edelpassand@radiomedix.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Izabela Tworowska</last_name>
    <phone>8328682812</phone>
    <email>itworowska@radiomedix.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Excel Diagnostics and Nuclear Oncology Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 4, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pb212-DOTAMTATE</keyword>
  <keyword>alpha-emitter-therapy</keyword>
  <keyword>neuroendocrine tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

